The FDA approved the first generic version of Xeloda an oral chemotherapy pill used to treat cancer of the colon...
Odonate Therapeutics, Inc. announced positive top-line results from CONTESSA, a Phase III study of tesetaxel in patients with metastatic breast cancer (MBC).
The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.